Gene expression regulation and cancer

Clinical and Translational Oncology

Volumn 8, Issue 11, 2006, Pages 780-787

  Dolores Delgado, M ^a   León, Javier ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Chromatin modifications; Enhancer; Oncogenic transcription factors; Promoter; RNA polymerase II; Transcriptional regulation

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P55; RETINOIC ACID; RNA POLYMERASE II; TRANSCRIPTION FACTOR; DNA DIRECTED RNA POLYMERASE; ONCOPROTEIN; TUMOR PROTEIN;

5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENETICS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CPG ISLAND; DNA DETERMINATION; DNA FLANKING REGION; DNA METHYLATION; DRUG TARGETING; ENHANCER REGION; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE REARRANGEMENT; GENE REPRESSION; GENE SILENCING; GENE STRUCTURE; HOUSEKEEPING GENE; HUMAN; HUMAN GENOME; INSULATOR ELEMENT; MALIGNANT NEOPLASTIC DISEASE; MAMMAL; NONHUMAN; ONCOGENE; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REGULATORY DNA SEQUENCE; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; CHROMATIN; GENETIC TRANSCRIPTION; GENETICS; PHYSIOLOGY; REVIEW; TRANSACTIVATION; ULTRASTRUCTURE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DNA METHYLATION; DNA-DIRECTED RNA POLYMERASES; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM PROTEINS; ONCOGENE PROTEINS; ONCOGENES; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 39049195055     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0132-7     Document Type: Article

References (39)

1. Sims RJ, 3rd, Mandal SS, Reinberg D. Recent highlights of RNA-polymerase-11-mediated transcription. Curr Opin Cell Biol. 2004;16:263-71.
2. Szutorisz H, Dillon N, Tora L. The role of enhancers as centres for general transcription factor recruitment. Trends Biochem Sci. 2005;30:593-9.
3. Fukue Y, Sumida N, Nishikawa J, Ohyama T. Core promoter elements of eukaryotic genes have a highly distinctive mechanical property. Nucleic Acids Res. 2004;32:5834-40.
4. Brown T. Assembly of the Transcription Initiation Complex: Genomes 3: Garland Science; 2006.
5. Kadonaga JT. The DPE, a core promoter element for transcription by RNA polymerase II. Exp Mol Med. 2002;54:259-64.
6. Mellor J. The dynamics of chromatin remodeling at promoters. Mol Cell. 2005;19:147-57.
7. West AG, Fraser P. Remote control of gene transcription. Hum Mol Genet. 2005; 14:101-11.
8. Dean A. On a chromosome far, far away: LCRs and gene expression. Trends Genet. 2006;22:38-45.
9. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet. 2001;17:520-7.
10. Li YJ, Fu XH, Liu DP, Liang CC. Opening the chromatin for transcription. Int J Biochem Cell Biol. 2004;36:1411-23.
11. Khorasanizadeh S. The nucleosome: From genomic organization to genomic regulation. Cell. 2004;116:259-72.
12. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem. 2006:75:243-69.
13. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer. 2005;41:2381-402.
14. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet. 2005;14:85-92.
15. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
16. Herranz M, Esteller M. New therapeutic targets in cancer: The epigenetic connection. Clin Transl Oncol. 2006;8:242-9.
17. Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002;12:73-9.
18. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: The industrial revolution of DNA around histones. Nat Rev Mol Cell Biol. 2006;7:437-47.
19. Kornberg RD. Mediator and the mechanism of transcriptional activation. Trends Biochem Sci. 2005;30:235-9.
20. Chadick JZ, Asturias FJ. Structure of eukaryotic Mediator complexes. Trends Biochem Sci 2005;30:264-71.
21. Asturias FJ. RNA polymerase 11 structure, and organization of the preinitiation complex. Curr Opin Struct Biol. 2004;14:121-9.
22. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P. A structural perspective of CTD function. Genes Dev. 2005;19:1401-15.
23. Goodrich JA, Kugel JF. Non-coding-RNA regulators of RNA polymerase ll transcription. Nat Rev Mol Cell Biol. 2006;7:612-6.
24. Pierotti M, Frattini M, Sozzi G, Croce C. Oncogenes. Cancer Medicine 7. London: BC Decker Inc; 2006, p. 68-84.
25. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci. 2004; 117:2173-81.
26. Iyer NG Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004;23:4225-51.
27. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006; 16:253-64.
28. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005;6:635-45.
29. Lutz W, Leon J, Eilers M. Contributions of Myc to tumorigenesis. Biochim Biophys Acta. 2002;1602:61-71.
30. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653-99.
31. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004-16.
32. Camos M, Colomer D. Molecular biology in acute leukemia. Clin Transl Oncol. 2006;8:550-9.
33. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acule leukemia: Variations on a theme. Oncogene. 2002;21:3422-44.
34. Daser A, Rabbitts TH. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol. 2005;15:175-88.
35. Willman CL, Hromas RA. Genomic Alterations and Chromosomal Aberrations in Human Cancer. Cancer Medicine 7. London: BC Decker Inc; 2006; p. 104-54.
36. Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol. 2005;23:1-9.
37. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16:1959-75.
38. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ. 2005; 10:451-42.
39. Levine AJ, Hu W, Feng Z. The P53 pathway: What questions remain to be explored. Cell Death Differ. 2006;13:1027-36.